NCT00781612 2025-12-24A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesGenentech, Inc.Phase 2 Active not recruiting720 enrolled
NCT00393783 2025-06-05Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and ImmunogenicityMemorial Sloan Kettering Cancer CenterPhase 1 Active not recruiting13 enrolled